AMGN241129P285000
- 2.00
- -3.50-63.64%
Amgen Newsroom
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
Boeing, NVIDIA Corp. Share Gains Contribute To Dow's 261-Point Jump
Deutsche Bank lowered amgen's target price to $285.
November 29th, Deutsche Bank: lowered Amgen's target price from $305 to $285, maintaining a "hold" rating. (Gelonghui)
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Multiple indications for Beigene's commercialized products have been included in the new version of the national medical insurance pharmaceutical catalog.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug Bai Ze An (Tislelizumab injection) and the BTK inhibitor Bai Yue Ze (Zerubutinib capsules) have each gained three new indications, and one indication has been included in the national health insurance directory; the product introduced through cooperation with luye pharma, Bai Tuo Wei (Goserelin microspheres for injection), has added one indication that is now included in the national health insurance directory; the product authorized and introduced by Amgen, Kai Luo Si (Carfilzomib for injection), has successfully been renewed. The national health insurance directory will formally implement from January 1, 2025. The company's products Bai Ze An and Bai Yue Ze.
Express News | Beigene: Bai Ze An added 13 indications to the medical insurance catalog.
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?
RBC Capital lowers Amgen's target price to $330.
November 28th, Glon Finance｜RBC Capital: Lowered Amgen's target price from $360 to $330, maintaining an "outperform" rating. (Glon Finance)
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Daily short sale tracking: GameStop's short volume increased by 1 million, with a short sale ratio of 12%
GameStop(GME.US) ranked top of the list had the largest change in short volume (1.49 million shares), and the short volume ratio of SLM Corp(SLM.US) reached 39.37%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
Today's Analyst Rating | Amgen Price Target Raised to $305 by Deutsche Bank, Applovin Price Target Raised to $400 by Jefferies
Nov 27, Wall Street analysts have updated their stock ratings today including $Amgen(AMGN.US)$ and $Applovin(APP.US)$.
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Amgen's Stock Closes off Lows to Avoid Worst Day in 24 Years as Weight-loss-drug Data Underwhelms